|
|||||
|
|
Extracellular heat shock protein 70 levels in tumour-bearing dogs and cats treated with radiation therapy and hyperthermia |
|
| Authors: | K J Nytko M S Weyland S Dressel-Böhm S Scheidegger L Salvermoser C Werner S Stangl A C Carpinteiro B Alkotub G Multhoff S Bodis C Rohrer Bley |
| Institution: | 1. Division of Radiation Oncology, Vetsuisse Faculty University of Zurich, Zurich, Switzerland;2. ZHAW School of Engineering, Zurich University of Applied Sciences, Winterthur, Switzerland;3. Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
TranslaTUM–Central Institute for Translational Cancer Research, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany Department of Radiology, University Hospital, LMU Munich, Munich, Germany;4. Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany TranslaTUM–Central Institute for Translational Cancer Research, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany;5. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland |
| Abstract: | Hyperthermia is a form of a cancer treatment which is frequently applied in combination with radiotherapy (RT) to improve therapy responses and radiosensitivity. The mode of action of hyperthermia is multifactorial; the one hand by altering the amount of the blood circulation in the treated tissue, on the other hand by modulating molecular pathways involved in cell survival processes and immunogenic interactions. One of the most dominant proteins induced by hyperthermia is the major stress-inducible heat shock protein 70 (Hsp70). Hsp70 can be found in the blood either as a free-protein (free HSP70) derived from necrotic cells, or lipid-bound (liposomal Hsp70) when it is actively released in extracellular vesicles (EVs) by living cells. The aim of the study was to evaluate the levels of free and liposomal Hsp70 before and after treatment with RT alone or hyperthermia combined with radiotherapy (HTRT) in dogs and cats to evaluate therapy responses. Peripheral blood was collected from feline and canine patients before and at 2, 4, 6 and 24 h after treatment with RT or HTRT. Hsp70 enzyme-linked immunosorbent assays (ELISAs) were performed to determine the free and liposomal Hsp70 concentrations in the serum. The levels were analysed after the first fraction of radiation to study immediate effects and after all applied fractions to study cumulative effects. The levels of free and liposomal Hsp70 levels in the circulation were not affected by the first singular treatment and cumulative effects of RT in cats however, after finalizing all treatment cycles with HTRT free and liposomal Hsp70 levels significantly increased. In dogs, HTRT, but not treatment with RT alone, significantly affected liposomal Hsp70 levels during the first fraction. Free Hsp70 levels were significantly increased after RT, but not HTRT, during the first fraction in dogs. In dogs, on the other hand, RT alone resulted in a significant increase in liposomal Hsp70, but HTRT did not significantly affect the liposomal Hsp70 when cumulative effects were analysed. Free Hsp70 was significantly induced in dogs after both, RT and HTRT when cumulative effects were analysed. RT and HTRT treatments differentially affect the levels of free and liposomal Hsp70 in dogs and cats. Both forms of Hsp70 could potentially be further investigated as potential liquid biopsy markers to study responses to RT and HTRT treatment in companion animals. |
| Keywords: | cancer canine feline liposomal Hsp70 radiotherapy thermoradiotherapy |